Investigation launched into CG Oncology officers for possible self-dealing harming shareholders
Kuehn Law, PLLC has launched an investigation into officers and directors of CG Oncology, Inc. for potential self-dealing and breaches of fiduciary duties. The probe aims to determine if shareholder rights have been violated, which could lead to damages and changes in corporate governance. Long-term investors are encouraged to contact the firm as there may be a limited timeframe for action.
How Investors May Respond To CG Oncology (CGON) Revenue Growth Alongside a Widening Net Loss
CG Oncology (CGON) reported Q2 results showing increased revenue of US$1.16 million, but also a widening net loss of US$79.06 million, indicating it remains a research-driven company. The investment narrative hinges on the success of its drug cretostimogene, with clinical trial readouts being key catalysts despite escalating cash burn and financing risks. While the stock has seen a strong year-to-date run, the growing losses and varied fair value estimates suggest a high degree of uncertainty among investors.
CG Oncology stock hits all-time high of 79.5 USD By Investing.com
CG Oncology's stock reached an all-time high of $79.50, trading just below its 52-week high with a 1-year return of 198% and 84% year-to-date gains. Despite strong investor confidence, InvestingPro analysis suggests the stock is overvalued and the company remains unprofitable, with analysts not expecting profitability this year. Recent positive Phase 3 trial results and subsequent analyst reports from H.C. Wainwright (Buy rating, $100 target) and Wolfe Research (Peerperform rating) highlight ongoing interest and varied expectations for the company's cretostimogene product.
CG Oncology (NASDAQ: CGON) insider flags $7.95M stock sale after recent disposals
An officer at CG Oncology, Ambaw Bellete, has filed a Rule 144 notice to sell up to 100,000 shares of the company's common stock, valued at approximately $7.95 million. This filing also details recent stock option exercises for 100,000 shares and significant open-market sales by Bellete totaling over $9 million in the past three months. The shares are expected to be sold through Morgan Stanley Smith Barney LLC.
CG Oncology stock hits all-time high of 79.5 USD By Investing.com
CG Oncology Inc.'s stock reached an all-time high of 79.5 USD, trading just below its 52-week high with a 1-year return of 198% and 84% year-to-date gains. Despite this impressive growth, InvestingPro analysis suggests the stock is overvalued, and the company remains unprofitable according to analysts. Recent developments include positive Phase 3 trial results published in Lancet Oncology and varied analyst ratings, reflecting ongoing interest and mixed expectations for the company's future.
CG Oncology (CGON) director sells 1,000 shares at $74.54
CG Oncology (CGON) director Leonard E. Post exercised a fully vested stock option for 1,000 shares at $0.60 per share and subsequently sold those 1,000 shares at $74.54 each on August 14, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following the sale, Post holds 104,077 director stock options directly.
CG Oncology (NASDAQ: CGON) insider lines up new stock sale
CG Oncology insider Ambaw Bellete has filed a Form 144 notice to sell 52,438 shares of common stock, valued at approximately $4.0 million, through Morgan Stanley Smith Barney LLC on August 17, 2026. This planned sale is linked to a stock option exercise. The filing also reveals that Bellete has made several previous open-market sales of CGON common stock in the past three months, including sales of 75,000 shares and multiple 50,000-share transactions.
CG Oncology (CGON) sees Foresite Capital report 4.9% beneficial stake via funds
Foresite Capital funds and James B. Tananbaum have reported beneficial ownership in CG Oncology (CGON) via a SCHEDULE 13G/A filing. While individual funds hold stakes under 5%, James B. Tananbaum, managing member of the involved Foresite Capital entities, is deemed to beneficially own 4,306,174 shares, representing 4.9% of CG Oncology's outstanding common stock. This aggregated stake is based on 88,640,375 shares outstanding as of August 4, 2026.
CG Oncology (CGON): RTW Investments takes 9.7% position, holding 8.5M shares
RTW Investments, LP and Roderick Wong, M.D. have reported a 9.7% beneficial ownership in CG Oncology, Inc. (CGON), totaling 8,514,590 common shares. These shares are held by RTW-managed funds, with RTW Investments and Dr. Wong sharing voting and dispositive power. The ownership percentage is based on 88,202,473 shares outstanding as of May 6, 2026.
CG Oncology's bladder cancer drug shows strong results with 75% response rate and no severe side effects.
CG Oncology's experimental drug cretositimogene grenadenorepvec (cret) has shown promising results in treating non-muscle invasive bladder cancer (NMIBC), achieving a 75% complete response rate and demonstrating a best-in-class safety profile with no severe adverse events. The company plans to submit a Biologics License Application (BLA) by Q4 2026. This positive progress has led to a significant increase of over 150% in CG Oncology's share price over the past year.
CGON (CGON) investor lists 25,989-share sale after series of stock disposals
An investor in CG Oncology, Inc. (CGON) has filed a Form 144, indicating a planned sale of 25,989 common shares with an aggregate market value of $1,973,970.86, expected on August 13, 2026. This filing also discloses a series of prior open-market sales by Ambaw Bellete over the last three months, including a significant transaction of 75,000 shares for $5,672,212.50 on August 6, 2026. The planned sale involves shares related to a stock option exercise and will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ.
CG Oncology (CGON): Wellington group discloses 5.3M-share, 6.04% ownership position
A group of affiliated Wellington entities has disclosed a beneficial ownership of 5,324,751 shares of CG Oncology (CGON) common stock, representing 6.04% of the class. This disclosure, filed via a SCHEDULE 13G/A, indicates shared voting power over 4,637,354 shares and shared dispositive power over all 5,324,751 shares. The shares are held by clients of various Wellington investment advisers, with no single client owning more than 5% of the class.
CG Oncology (CGON) Faces A Fair Value Gap Following Its Latest Earnings
CG Oncology recently reported its Q2 and H1 2026 earnings, showing revenue of US$1.16 million for the quarter and a net loss of US$79.06 million. Despite being a loss-making company, a discounted cash flow (DCF) model by Simply Wall St estimates a fair value of US$542.38 per share, significantly higher than its current trading price of US$76.99, indicating a large potential undervaluation. However, the company still faces risks associated with ongoing losses and multiple late-stage clinical trials.
CGON (NASDAQ: CGON) holder files to sell 32,137 shares after option exercise
An insider at CG Oncology, Ambaw Bellete, has filed to sell 32,137 common shares of CGON through Morgan Stanley Smith Barney LLC. This proposed sale is linked to a stock option exercise on August 12, 2026, with an aggregate market value of over $2.5 million. The filing also disclosed multiple prior open-market sales by Bellete in July and August 2026.
CGON (CGON) insider Ambaw Bellete plans 50,000-share stock sale
CG Oncology (CGON) insider Ambaw Bellete plans to sell 50,000 shares of common stock on August 11, 2026, through a stock option exercise settled in cash. The estimated value of this planned sale is $3,810,255.00. This disclosure also reveals several recent sales of CGON common stock by Ambaw Bellete, totaling over 290,000 shares, between July 15 and August 10, 2026, with significant dollar values.
CG Oncology (NASDAQ:CGON) Hits New 52-Week High - Should You Buy?
CG Oncology (NASDAQ:CGON) recently reached a new 52-week high of $77.49, with a current trading price near $76.98. The clinical-stage biopharmaceutical company has a "Moderate Buy" consensus rating from analysts, with several price target increases, but reported a quarterly loss of $0.90 per share, missing estimates. Insider selling also occurred, with directors offloading shares totaling approximately $2.66 million in the last quarter.
CGON (CGON) insider plans 50,000-share stock sale after option exercise
CG Oncology, Inc. (CGON) filed a Form 144 indicating an insider's plan to sell 50,000 shares of common stock, valued at $3,770,580.00, on August 10, 2026, following a stock option exercise. The filing also details previous common stock sales by Ambaw Bellete over the past three months, including significant transactions in early August 2026. This activity relates to transparent regulatory filings regarding large stock sales.
HC Wainwright Has Weak Estimate for CG Oncology Q3 Earnings
HC Wainwright has lowered its Q3 2026 EPS estimate for CG Oncology (NASDAQ:CGON) to a loss of $0.96 per share from a previous loss estimate of $0.78, while maintaining a "Buy" rating and $100 price target. This revision follows CG Oncology's latest quarterly results, where the company reported a $0.90-per-share loss, missing the $0.66 consensus estimate, despite revenue of $1.16 million exceeding forecasts of $0.36 million. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and an average price target of $83.18, although some analysts have adjusted their targets or ratings.
Bank of America Securities Reaffirms Their Buy Rating on CG Oncology, Inc. (CGON)
Bank of America Securities reiterated a Buy rating on CG Oncology, Inc. (CGON) with an $88.00 price target. This affirmation follows the company's Q2 earnings report, which showed $1.16 million in revenue and a net profit of $0, a significant improvement from the prior year's net loss. Insider sentiment for CGON is positive, with notable share purchases by a director.
Enterprise value to EBITDA forward of CG Oncology, Inc. – NASDAQ:CGON
This page from TradingView provides financial information for CG Oncology, Inc. (NASDAQ: CGON), specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed at the time of viewing and presents various navigation options related to markets, products, and community features of the TradingView platform.
Bank of America Corp DE Grows Holdings in CG Oncology, Inc. $CGON
Bank of America Corp DE increased its stake in CG Oncology, Inc. by 21.8% in the first quarter, bringing its total holdings to 1.45 million shares valued at approximately $98.1 million. Institutional investors now own 26.56% of the company's stock, while insider transactions show mixed activity with significant purchases by one director and sales by another. Analysts maintain a "Moderate Buy" consensus with an average price target of $83.18, despite the company reporting a wider-than-expected quarterly loss of $0.90 per share, though revenue surpassed estimates.
CG Oncology (NASDAQ:CGON) Posts Earnings Results, Misses Expectations By $0.24 EPS
CG Oncology (NASDAQ:CGON) reported a wider-than-expected quarterly loss of $0.90 per share, missing consensus estimates by $0.24, despite revenue of $1.16 million surpassing expectations. The stock saw a slight increase to $75.10, near its 52-week high, and maintains a "Moderate Buy" consensus rating with an average price target of $83.18. However, insider selling worth $2.66 million and a lowered intermediate-term earnings forecast by one analyst present a mixed outlook alongside positive analyst sentiment and increased institutional ownership.
Insider Ambaw Bellete plans CGON (CGON) stock sale after large prior trades
Ambaw Bellete, an insider at CG Oncology, Inc. (CGON), has filed a Form 144 indicating an intent to sell up to 9,250 shares of common stock on August 7, 2026, through Morgan Stanley Smith Barney LLC. This filing also details several significant common stock sales by Bellete in the preceding three months, including transactions on August 6th, August 5th, and July 15th, 2026. The Form 144 provides transparency on planned stock sales and recent trading activities by company insiders.
How Investors Are Reacting To CG Oncology (CGON) Wider Quarterly Loss Amid Promising Phase 3 Bladder Cancer Data
CG Oncology recently reported a wider quarterly loss of US$79.06 million, despite generating US$1.16 million in revenue. This financial performance contrasts with promising Phase 3 data for its bladder cancer treatment, cretostimogene grenadenorepvec, which met its primary endpoint. The article discusses how investors are weighing the company's cash-burning status and financing risk against its strong clinical progress and upcoming regulatory milestones for its key drug.
BofA Adjusts Price Target on CG Oncology to $88 From $87
BofA Securities has raised its price target for CG Oncology (CGON) shares to $88 from $87, while maintaining a Buy rating. This adjustment follows a previous price target revision by RBC, which lowered its target to $79 from $81. The article highlights recent news regarding CG Oncology, including Q2 earnings results and progress in its clinical trials for bladder cancer treatments.
Press Release: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
This press release details CG Oncology's financial results for the second quarter of 2026 and provides key business updates. It covers the company's financial performance, including revenue and expenses, alongside progress on its pipeline and strategic initiatives.
How Investors Are Reacting To CG Oncology (CGON) Wider Quarterly Loss Amid Promising Phase 3 Bladder Cancer Data
CG Oncology recently reported a wider net loss of US$79.06 million in Q2 2026, while generating US$1.16 million in revenue. Despite the financial setback, the company is advancing its lead drug, cretostimogene grenadenorepvec, for non-muscle invasive bladder cancer, with promising Phase 3 data published in The Lancet Oncology. The article discusses how investors are balancing the widening losses with the strong clinical data and upcoming regulatory milestones, highlighting the tension between the company's cash-burning status and its potential for a commercially relevant therapy.
CG Oncology, Inc. Stock 12‑Month Price Target Raised to $91.15, Implies 26% Upside
CG Oncology, Inc.'s average 12-month stock price target has increased from $90.69 to $91.15, based on estimates from 13 analysts, suggesting a 26% potential upside from its August 5 closing price. The consensus rating for CGON remains a "Buy" among 15 analysts, with 14 recommending a buy and 1 recommending a hold.
Insider (NASDAQ: CGON) files to sell 75,000 shares after recent stock sales
Ambaw Bellete, an insider at CG Oncology, Inc. (NASDAQ: CGON), has filed to sell 75,000 shares of common stock through Morgan Stanley's Executive Financial Services program, linked to a stock option exercise on August 6, 2026. This proposed sale has an aggregate market value of $5,672,212.50. The filing also details multiple prior stock sales by Bellete over the past three months, with significant dollar values, indicating a pattern of recent disposals.
CG Oncology earnings up next amid bladder cancer therapy push By Investing.com
CG Oncology Inc. is set to report second-quarter earnings, with analysts expecting a narrower loss as the company progresses towards a regulatory filing for its bladder cancer treatment. The biotech aims to complete its Biologics License Application by Q4 2026, positioning it for potential FDA approval next year. Investors will be focused on the regulatory timeline, competitive data, ongoing trial updates, and the company's cash burn.
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
CG Oncology, Inc. (CGON) reported a Q2 loss of $0.9 per share, missing the Zacks Consensus Estimate of a $0.7 loss, and posted revenues of $1.16 million, which fell short of estimates by 59.02%. Despite the earnings miss, the company's shares have risen 74.4% year-to-date, significantly outperforming the S&P 500. The stock currently holds a Zacks Rank #3 (Hold) based on its mixed estimate revisions trend.
CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
CG Oncology Inc. reported its second-quarter 2026 financial results, highlighting significant progress in clinical, regulatory, manufacturing, and commercial-readiness initiatives. Key milestones include anticipated Phase 3 topline data for PIVOT-006, expected BLA completion for HR BCG-unresponsive NMIBC in Q4 2026, and the publication of BOND-003 Cohort C Study Results in The Lancet Oncology. The company maintains a strong financial position with approximately $1.0 billion in cash, cash equivalents, and marketable securities, sufficient to fund operations through 2029.
CG Oncology expects bladder cancer trial data soon; cash through 2029
CG Oncology reported a Q2 2026 net loss of $79.1 million on $1.2 million in revenue, primarily due to increased R&D and G&A expenses. The company maintains a strong cash position of approximately $1.0 billion, which is projected to fund operations through 2029, supporting ongoing clinical trials and regulatory milestones. Key upcoming events include topline data from the Phase 3 PIVOT-006 trial and completion of a Biologics License Application (BLA) for high-risk BCG-unresponsive NMIBC in Q4 2026.
Dimensional Fund Advisors LP Sells 22,459 Shares of CG Oncology, Inc. $CGON
Dimensional Fund Advisors LP has reduced its stake in CG Oncology (NASDAQ:CGON) by selling 22,459 shares, though it still holds 438,673 shares valued at approximately $29.7 million. Despite this sale, institutional investors collectively own 26.56% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $81.73. The company recently reported a wider-than-expected quarterly loss of $0.71 per share but exceeded revenue expectations, with its stock opening at $71.40.
CGON (CGON) insider Ambaw Bellete plans 25,000-share stock sale via broker
CG Oncology, Inc. (CGON) insider Ambaw Bellete has filed a Form 144 notice to sell up to 25,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,837,500.00. The shares, acquired via a stock option exercise, are planned for sale on or after August 5, 2026. This filing also discloses several previous sales by Bellete in July 2026, totaling significant share amounts and market values.
Price to sales forward of CG Oncology, Inc. – NASDAQ:CGON
This article displays the "Price to sales forward" for CG Oncology, Inc. (NASDAQ: CGON) on TradingView. It appears to be a financial data point without additional explanatory text or analysis. The page is primarily a data display with navigation and disclaimer information.
Price to earnings forward of CG Oncology, Inc. – NASDAQ:CGON
This article provides the "Price to earnings forward" metric for CG Oncology, Inc. (NASDAQ: CGON) on TradingView. It appears to be a financial data point displayed within a larger financial analysis platform. The specific value and change percentage are indicated as data fields.
H.C. Wainwright Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $100
H.C. Wainwright has reiterated its Buy rating on CG Oncology (CGON.US) and maintained a target price of $100. This continued positive outlook suggests the firm's confidence in the company's future performance.
What CG Oncology (CGON)'s Pivotal BOND-003 Phase 3 Data Means For Shareholders
CG Oncology's Phase 3 BOND-003 data for cretostimogene grenadenorepvec in bladder cancer highlights statistically significant complete responses and a favorable safety profile, reinforcing its potential as a meaningful therapy. This positive clinical data strengthens the investment case for CG Oncology, though the company still faces challenges including lack of approved products, significant cash burn, and ongoing legal issues. Investors are encouraged to weigh these clinical milestones against financial risks like potential dilution as the company moves towards commercialization.
CGON|CG Oncology Inc|Price:69.180|Chg%:-3.440
This article provides a comprehensive stock analysis of CG Oncology Inc (CGON) from TradingKey. The company's fundamentals are considered healthy with high growth potential, and its valuation is deemed fairly valued within the Biotechnology & Medical Research industry. Analysts have given a "Buy" rating with a target price of 90.25, indicating a 22.76% upside, despite a sideways trading pattern over the last month.
What CG Oncology (CGON)'s Pivotal BOND-003 Phase 3 Data Means For Shareholders
CG Oncology recently published pivotal Phase 3 BOND-003 data in The Lancet Oncology, showing that its monotherapy, cretostimogene grenadenorepvec, achieved significant complete responses with durable outcomes and a favorable safety profile for high-risk bladder cancer. This positive report strengthens the company's investment narrative by reinforcing regulatory and physician confidence in the drug. While this publication and approaching PIVOT-006 readout are key clinical milestones, investors also face risks such as the company's lack of approved products, significant annual burn rate, ongoing legal appeals, and potential future dilution for commercialization funding.
Law firm investigates CG Oncology officers for possible self-dealing harming shareholders
Kuehn Law, PLLC is investigating officers and directors of CG Oncology, Inc. for potential breaches of fiduciary duties through self-dealing. This probe could result in damages for shareholders and corporate governance reforms, and long-term shareholders are encouraged to contact the law firm.
CGON (CGON) insider files to sell 4,303 shares after option exercise
An insider at CG Oncology, Inc. (CGON) has filed a Form 144 notice to sell 4,303 common shares after exercising stock options on July 29, 2026. This sale will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services. The filing also details prior large sales of CGON common stock by Ambaw Bellete, the selling security holder, totaling over 200,000 shares in the three months preceding this notice.
What CG Oncology (CGON)'s Pivotal BOND-003 Phase 3 Data Means For Shareholders
CG Oncology's recently published Phase 3 BOND-003 data in The Lancet Oncology indicates that its monotherapy, cretostimogene grenadenorepvec, achieved significant complete responses with durable outcomes and a favorable safety profile for high-risk bladder cancer. This strengthens the company's investment narrative by reinforcing regulatory and physician confidence, but it still faces challenges like a lack of approved products, annual cash burn, and the ANI legal appeal. Shareholders need to weigh these clinical milestones against potential dilution and the company's current valuation.
CGON (CGON) insider Ambaw Bellete files to sell 50,000 shares
Ambaw Bellete, an insider at CG Oncology, Inc. (CGON), has filed a Form 144 indicating an intention to sell 50,000 shares of common stock. This planned sale, valued at approximately $3.6 million, is scheduled for on or after July 28, 2026, and is connected to a stock option exercise. The filing also reveals prior sales totaling over 150,000 shares within the last three months.
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $108
LifeSci Capital has reiterated its Buy rating on CG Oncology (CGON.US) and maintained its target price of $108. This indicates continued confidence from the firm in the company's prospects.
About 81% of BOND-003 patients maintained their bladders at 24 months
CG Oncology (NASDAQ: CGON) announced the publication of pivotal Phase 3 BOND-003 Cohort C study results in The Lancet Oncology. The study evaluated cretostimogene grenadenorepvec monotherapy for high-risk, BCG-unresponsive non-muscle invasive bladder cancer and met its primary endpoint with a 75.5% complete response rate. Key findings include durable responses, high bladder preservation rates (81% at 24 months), and a favorable safety profile with no Grade 3 or higher treatment-related adverse events.
BlackRock, Inc. (CGON) discloses 6.8% beneficial ownership in CG Oncology
BlackRock, Inc. has filed an amended Schedule 13G disclosing a 6.8% beneficial ownership in CG Oncology (CGON), amounting to 6,023,696 shares of common stock. BlackRock holds sole voting power over 5,914,671 shares and sole dispositive power over all 6,023,696 shares. The filing specifies that while various persons may receive dividends or sale proceeds from these shares, no single individual holds more than five percent of CG Oncology's outstanding common shares.
CGON (CGON) filer discloses 50,000-share sale plan and recent stock sales
An affiliate of CG Oncology (CGON), Ambaw Bellete, has filed a notice to sell 50,000 shares of common stock, valued at $3,627,995.00, through a stock option exercise on July 27, 2026. The filing also reports prior sales by the same individual, including 50,000 shares for $3,588,620.00 on July 23, 2026, and 52,438 shares for $3,816,007.65 on July 15, 2026. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker for these transactions.
CG Oncology, Inc. Revenue Breakdown – NASDAQ:CGON
CG Oncology, Inc. (NASDAQ: CGON) generated $4.04 million USD in revenue last year, primarily from its Backbone Bladder-sparing Therapeutic segment. This marks a significant increase from $1.14 million USD in the previous year. The United States was the sole contributor to this revenue, accounting for the entire $4.04 million USD.
